Effects of Hydrogen Gas Inhalation on Community-Dwelling Adults of Various Ages: A Single-Arm, Open-Label, Prospective Clinical Trial
Rahman MH et al. · Antioxidants (Basel). 2023;12(6):1241.
Study at a glance
Human
Community-dwelling adults aged 40–70 years without diagnosed Alzheimer’s disease
2% H₂ in filtered air through a nasal cannula for 30 minutes daily · 2% H₂ + 98% filtered air.
30 minutes daily for 4 weeks
Several blood biomarkers changed from baseline, while white-cell counts did not. The design cannot establish whether H₂ caused the changes or whether they represent clinical cognitive benefit.
Uncontrolled before-and-after study with numerous biomarkers, no diagnosed Alzheimer’s population and no basis for inferring clinical efficacy. The device company assisted the study.
What kind of evidence is this?
Human
Single-arm open-label prospective clinical trial
Other neurological conditions
Inhaled H₂
Information not yet classified
Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.
Methods
Community-dwelling adults aged 40–70 years without diagnosed Alzheimer’s disease
54 screened and enrolled; 51 described in the analyzed cohort
30 minutes daily for 4 weeks
2% H₂ in filtered air through a nasal cannula for 30 minutes daily
H₂ diluted in filtered ambient air — not Brown’s gas.
2% H₂ + 98% filtered air.
Not reported — device output and total gas flow were not stated, so absolute H₂ flow cannot be calculated.
No supplemental O₂ was reported; O₂ from filtered ambient air was present, but its absolute flow cannot be calculated.
No control group
Outcomes and reported result
White-cell counts, oxidative-stress markers and multiple blood biomarkers associated with cognitive or neurodegenerative research
Several blood biomarkers changed from baseline, while white-cell counts did not. The design cannot establish whether H₂ caused the changes or whether they represent clinical cognitive benefit.
Intervention, full methods, results, registry and funding statements checked in the open-access full text; gas flow remains unreported.
A reported association, difference or mechanism is not automatically a clinical benefit.
Limitations and applicability
Uncontrolled before-and-after study with numerous biomarkers, no diagnosed Alzheimer’s population and no basis for inferring clinical efficacy. The device company assisted the study.
Community-dwelling adults aged 40–70 under this short biomarker protocol; not patients with confirmed Alzheimer’s disease.
No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.
Sources and record status
PMID: 37371971 · DOI: 10.3390/antiox12061241
Open-access full text is available through PMC and the publisher.
Open-access PMC and publisher full texts plus PubMed record.
10 August 2026
Help people check the facts before they buy.
Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.
Help us correct the recordReport a discrepancy
Send the exact difference between this page and the linked source. The study reference is attached automatically.